Australia - English - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - rufinamide, quantity: 400 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; maize starch; hypromellose; lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; macrogol 8000; titanium dioxide; purified talc; iron oxide red - inovelon is indicated as adjunctive therapy in the treatment of seizures associated with lennox gastaut syndrome in patients 4 years of age and older

Australia - English - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - rufinamide, quantity: 200 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; maize starch; hypromellose; lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; macrogol 8000; titanium dioxide; purified talc; iron oxide red - inovelon is indicated as adjunctive therapy in the treatment of seizures associated with lennox gastaut syndrome in patients 4 years of age and older

Australia - English - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - rufinamide, quantity: 100 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; maize starch; hypromellose; lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; macrogol 8000; titanium dioxide; purified talc; iron oxide red - inovelon is indicated as adjunctive therapy in the treatment of seizures associated with lennox gastaut syndrome in patients 4 years of age and older

Ireland - English - HPRA (Health Products Regulatory Authority)

marion merrell limited - vigabatrin - powder for oral solution - 1 grams

Ireland - English - HPRA (Health Products Regulatory Authority)

marion merrell limited - vigabatrin - powder for oral solution - 2 grams

Ireland - English - HPRA (Health Products Regulatory Authority)

marion merrell limited - vigabatrin - powder for oral solution - 3 grams

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - carbamazepine, quantity: 20 mg/ml - oral liquid, suspension - excipient ingredients: hyetellose; methyl hydroxybenzoate; purified water; dispersible cellulose; propyl hydroxybenzoate; sorbitol solution (70 per cent) (non-crystallising); peg-8 stearate; sorbic acid; propylene glycol; saccharin sodium; flavour - 1. epilepsy: complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalisation; generalised tonic-clonic seizures; mixed seizure patterns incorporating the above. tegretol is suitable for monotherapy and combination therapy. tegretol is usually not effective in absence seizures, atonic seizures and myoclonic seizures and should not be used for status epilepticus (see "precautions"). 2. trigeminal neuralgia: for relief of pain in idiopathic trigeminal neuralgia and trigeminal neuralgia due to multiple sclerosis; and in idiopathic glossopharyngeal neuralgia. (tegretol is not a simple analgesic and is not intended for trivial facial pain or headache). 3. mania and bipolar affective disorders: treatment of mania and maintenance treatment of bipolar affective disorders to prevent or attenuate recurrence.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - carbamazepine, quantity: 200 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; carmellose sodium - 1. epilepsy: complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalisation; generalised tonic-clonic seizures; mixed seizure patterns incorporating the above. tegretol is suitable for monotherapy and combination therapy. tegretol is usually not effective in absence seizures, atonic seizures and myoclonic seizures and should not be used for status epilepticus (see "precautions"). 2. trigeminal neuralgia: for relief of pain in idiopathic trigeminal neuralgia and trigeminal neuralgia due to multiple sclerosis; and in idiopathic glossopharyngeal neuralgia. (tegretol is not a simple analgesic and is not intended for trivial facial pain or headache). 3. mania and bipolar affective disorders: treatment of mania and maintenance treatment of bipolar affective disorders to prevent or attenuate recurrence.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - phenytoin - suspension - phenytoin 125 mg / 5 ml - phenytoin - phenytoin - for the control of tonic clonic (grand- mal) and psychomotor (temporal lobe seizures).

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - lamotrigine, quantity: 200 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; sodium starch glycollate; maize starch; lactose monohydrate - antiepileptic drug for the treatment of partial and generalised seizures in adults and children over 12 years of age.,there is extensive experience with lamotrigine used initially as add-on therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs.,initial monotherapy treatment in newly diagnosed paediatric patients is not recommended (see section 5.1 pharmacodynamic properties, clinical trials).